In breast cancer cells, hyperoside has been reported to modulate intracellular ROS levels and inhibit the NF-κB pathway, leading to a decrease in the expression of anti-apoptotic genes such as XIAP and Bcl-2, while promoting the accumulation of Bax, a pro-apoptotic factor [24]. Here, BCL2 is linked to breast carcinoma.